Health Care Select Sector SPDR Fund (XLV)
| Assets | $35.59B |
| Expense Ratio | 0.08% |
| PE Ratio | 20.73 |
| Shares Out | 249.27M |
| Dividend (ttm) | $2.44 |
| Dividend Yield | 1.69% |
| Ex-Dividend Date | Sep 22, 2025 |
| Payout Frequency | Quarterly |
| Payout Ratio | 35.11% |
| Volume | 9,202,897 |
| Open | 144.12 |
| Previous Close | 144.12 |
| Day's Range | 143.28 - 144.66 |
| 52-Week Low | 127.35 |
| 52-Week High | 155.02 |
| Beta | 0.64 |
| Holdings | 63 |
| Inception Date | Dec 16, 1998 |
About XLV
Fund Home PageThe Health Care Select Sector SPDR Fund (XLV) is an exchange-traded fund that is based on the S&P Health Care Select Sector index. The fund tracks health care stocks from within the S&P 500 Index, weighted by market cap. XLV was launched on Dec 16, 1998 and is issued by State Street.
Top 10 Holdings
57.03% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 12.68% |
| Johnson & Johnson | JNJ | 8.63% |
| AbbVie Inc. | ABBV | 7.85% |
| UnitedHealth Group Incorporated | UNH | 6.20% |
| Abbott Laboratories | ABT | 4.45% |
| Merck & Co., Inc. | MRK | 4.23% |
| Thermo Fisher Scientific Inc. | TMO | 3.90% |
| Intuitive Surgical, Inc. | ISRG | 3.08% |
| Amgen Inc. | AMGN | 3.05% |
| Pfizer Inc. | PFE | 2.96% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 22, 2025 | $0.62487 | Sep 24, 2025 |
| Jun 23, 2025 | $0.63038 | Jun 25, 2025 |
| Mar 24, 2025 | $0.56454 | Mar 26, 2025 |
| Dec 23, 2024 | $0.62166 | Dec 26, 2024 |
| Sep 23, 2024 | $0.57723 | Sep 25, 2024 |
| Jun 24, 2024 | $0.57253 | Jun 26, 2024 |
Performance
XLV had a total return of -3.20% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.37%.
News
What AMD's OpenAI deal means for Nvidia, healthcare stocks see major gains in 2025
Morning Brief: Market Sunrise anchor Ramzan Karmali examines the biggest market news and stories for October 7, 2025. CFRA research analyst Angelo Zino comes on the program to talk more about AMD's AI...
Confluence of factors are bringing investment into biotech sector, says StemPoint's Michelle Ross
Michelle Ross, StemPoint Capital CIO, joins 'Closing Bell' to discuss Ross' thoughts on the recent news in the biotech space, what the CIO expects to continue and much more.
How to trade the health care break out
The health care sector up 6.5% in one week. The Investment Committee debate how to trade the space.
5 Dividend Stocks I Can't Wait To Buy In October (Plus Macro Update)
The US stock market is highly concentrated, with technology and tech-related stocks now comprising about 55% of total market cap. This concentration justifies higher valuation multiples for SPY, as te...
‘Fast Money' traders talk opportunities in health care stocks
The Fast Money traders discuss why health care stocks look attractive on valuations, how underweight positioning could drive sustainability, why recent White House policy moves may be a “gift” to phar...
Every pharma company I cover has U.S. production so tariffs are more bark than bite: BMO's Seigerman
Evan Seigerman, BMO Capital Markets head of healthcare research, joins 'Closing Bell' to discuss President Trump's latest tariff announcement on pharmaceutical companies, where execution needs to happ...
2 Call Writing Funds Providing Monthly Distributions For Passive Income
Call writing closed-end funds can offer attractive monthly distributions, along with the opportunity to trade at discounts to their historical net asset values. That discount can create an opportunity...
XLV: Market Overreaction Could Drive Double Digit Shareholder Yield
Healthcare sector trades at a historic discount due to patent expirations, managed care uncertainty, and drug pricing proposals, but pessimism is overdone. Key catalysts include potential M&A activity...
Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.
Last week, the SPDR S&P Biotech ETF surged 6%.
XLV Vs. IHE: Will Pharmaceuticals Outperform Healthcare?
Healthcare is a defensive sector with strong long-term growth drivers like demographics, innovation, and rising healthcare spending. I rate XLV a buy due to its diversified exposure across healthcare ...
Healthcare Stocks Are ‘Priced at Panic Levels.' It's Time to Buy.
They're bargains right now, according to two key measures. Expert Jim Paulsen won't venture a guess when the prices will recover.
Healthcare industry can handle and absorb tariffs, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Power Lunch' to discuss what tariffs mean for the pharma industry, what could be a blockbuster for Eli Lilly and much more.
Health care sector is resilient, 'won't stay down forever', says Evan May Wealth's Brooke Evans
Brooke May, Evans May Wealth managing partner, joins 'Closing Bell Overtime' to talk what sectors she is keeping an eye on in this market.
Healthcare Stocks Are Trading at Their Biggest Discount in 30 Years. Why a Turnaround May Have Already Started.
For investors worried about elevated market valuations, they may be just what the doctor ordered.
Gill: We're at a real inflection point for healthcare
Lisa Gill, JP Morgan healthcare analyst, on “Worldwide Exchange,” says healthcare is at an inflection point, with UnitedHealth poised for long-term gains as big investors bet on a turnaround.
Mizuho's Jared Holz on how to play the underperforming health care sector
Jared Holz, Mizuho Securities healthcare sector strategist, joins 'The Exchange' to discuss Insmed's lung drug being greenlit by the FDA and his read on the healthcare sector.
Final Trades: Netflix, Wynn Resorts, Buckle and the XLV
The Investment Committee give you their top stocks to watch for the second half.
US FDA announces new program to boost domestic drug manufacturing
The U.S. Food and Drug Administration on Thursday announced a new program to strengthen the domestic pharmaceutical supply chain, by facilitating construction of manufacturing sites in the United Stat...
Key ETF Asset Class Performance
The market ended the month of July on a down note, but the S&P 500 still ended the month with a gain of 2.3%. While domestic equities posted small gains in July, there was quite a bit of disparity amo...
Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector
Umer Raffat, Evercore ISI senior analyst, joins 'The Exchange' to discuss if there's a turnaround coming for the health care sector.
Managed care needs to improve to improve health care sector, says Mizuho's Jared Holz
Jared Holz, Mizuho health care sector strategist, joins 'The Exchange' to discuss the pain in the health care sector and if there are any opportunity plays within.
Trump's deadline looms for Big Pharma companies facing new tariffs
'The Big Money Show' panel discusses President Donald Trump's pharmaceutical tariff strategy.
XLV: Life Expectancy, Patents, And A Positive Outlook Will Pave The Way
The life expectancy has increased in the U.S. and worldwide, contributing to healthcare companies retaining their patients for longer periods. Investors pay low fees to hold XLV, since the expense rat...
Heard on the Street: Why pharma stocks have outperformed the broader market since Trump threatened the industry with a 200% tariff
A generous grace period would give drugmakers time to sidestep most of the pain of looming duties.